Skip to main content
    E

    Edwards Lifesciences Corp (EW)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $105.39
    -1.72 (-1.61%)

    Market Cap: $61.59B

    Last updated: Nov 17, 2026 at 4:35 PM ET

    Edwards Lifesciences Corp (EW) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Edwards Lifesciences (EW) has a market cap of $61.59B and an enterprise value of $59.16B. Its trailing P/E is 35.8x.

    Total Valuation

    Enterprise value is 3.95% below the market cap, as cash exceeds debt.

    Market Cap$61.59B
    Enterprise Value$59.16B
    Latest price (Nov 17, 2026)$105.39

    Key Dates

    The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 8, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.02% in the quarter ended Sep 30, 2026 and shrank 1.77% a year over 2 years.

    Shares Outstanding576.30M
    Shares Change (YoY)-1.44%
    Shares Change (QoQ)-0.02%
    Share Count Growth (2Y CAGR)-1.77%

    Valuation Ratios

    Sales and book value multiples are 9.1x and 5.6x. Its year-end P/E ranged from 28.3x to 58.1x from 2016 to 2025.

    P/E Ratio35.8x
    Forward P/E34.0x
    P/S Ratio9.1x
    Forward P/S9.0x
    P/B Ratio5.6x
    P/TBV Ratio7.8x
    P/FCF Ratio42.6x
    P/OCF Ratio35.9x
    PEG Ratio3.0

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 41.0x EBITDA and 40.9x free cash flow.

    EV / Earnings58.3x
    EV / Sales8.9x
    EV / EBITDA41.0x
    EV / FCF40.9x

    Price Statistics

    The stock is up 22.12% over 52 weeks and trades 15.64% above its 50-day average.

    Beta (1Y)0.54
    52-Week Change+22.12%
    1-Month Change+20.83%
    3-Month Change+14.21%
    6-Month Change+28.27%
    5-Year Change-23.21%
    10-Year Change+189.89%
    Total Return (1Y)+22.12%
    Total Return (3Y CAGR)+16.35%
    Total Return (5Y CAGR)-2.07%
    Return vs SPY (1Y)+13.85%
    Max Drawdown (1Y)-13.19%
    Max Drawdown (3Y)-37.53%
    Sharpe Ratio (1Y)0.89
    Correlation with SPY (1Y)0.29
    50-Day Average$91.14
    200-Day Average$86.58
    52-Week Range$74.66 to $108.00
    RSI (14 Days)72.7
    Average Volume (20 Days)5.04M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.60x current liabilities, and total debt is 0.06x shareholder equity.

    Current Ratio4.60x
    Quick Ratio3.86x
    Debt / Equity0.06x
    Debt / EBITDA0.48x
    Debt / FCF0.48x
    Interest Coverage55.12x

    Returns and Efficiency

    Return on invested capital is 7.47% over the last 12 months, against a 5-year average of 8.47%.

    Return on Equity (ROE)9.34%
    Return on Assets (ROA)7.17%
    Return on Invested Capital (ROIC)7.47%
    ROE (5Y Average)25.01%
    ROA (5Y Average)18.14%
    ROIC (5Y Average)8.47%
    Asset Turnover0.49x
    Inventory Turnover1.28x
    Receivables Turnover7.05x
    Cash Conversion Cycle286 days

    Taxes

    Income tax took 31.05% of pretax income over the last 12 months.

    Income Tax (TTM)$444.70M
    Effective Tax Rate31.05%

    Scores

    EW has an Altman Z-Score of 14.20, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score14.20
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $6.67B over the last 12 months is up 13.44% from the 12 months before.

    Revenue$6.67B
    Revenue Growth (YoY)+13.44%
    Gross Profit$5.21B
    Operating Income$1.44B
    Pretax Income$1.43B
    Net Income$1.01B
    Reported EPS (TTM)$2.94

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 76.80% of the $14.14B in total assets.

    Cash and Equivalents$3.11B
    Total Debt$679.60M
    Net Cash$2.43B
    Net Cash Per Share$4.22
    Working Capital$5.67B
    Shareholder Equity$10.86B
    Book Value Per Share$18.85
    Tangible Book Value$7.75B
    Tangible Book Per Share$13.44
    Total Assets$14.14B
    Total Liabilities$3.18B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $292.80M of capital spending, operating cash flow left $1.42B of free cash flow.

    Operating Cash Flow$1.72B
    Capital Expenditures$292.80M
    Free Cash Flow$1.42B
    FCF Per Share$2.47
    Depreciation and Amortization$171.20M
    Share Repurchases$754.60M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 21.59%, against a 5-year average of 27.64%.

    Gross Margin78.02%
    Operating Margin21.59%
    Pretax Margin21.46%
    Net Margin15.20%
    FCF Margin21.34%
    Gross Margin (5Y Average)79.57%
    Operating Margin (5Y Average)27.64%
    Net Margin (5Y Average)37.01%

    Growth

    Revenue grew 10.77% a year over 3 years, and EPS 1.06% a year.

    Revenue Growth (3Y CAGR)+10.77%
    Revenue Growth (5Y CAGR)+6.70%
    EPS Growth (3Y CAGR)+1.06%
    EPS Growth (5Y CAGR)+6.71%
    FCF Growth (3Y CAGR)+11.10%
    FCF Growth (5Y CAGR)+15.58%
    Operating Income Growth (3Y CAGR)-5.51%
    Book Value Per Share Growth (2Y CAGR)+27.34%
    Tangible Book Per Share Growth (2Y CAGR)+23.30%

    Revenue and profit by year

    Dividends and Yields

    EW does not pay a dividend. Its free cash flow yield is 2.34%.

    Earnings Yield2.79%
    FCF Yield2.34%
    Buyback Yield0.93%
    Shareholder Yield0.93%

    Stock Splits

    The last split was a 3-for-1 forward split on Jun 1, 2020.

    Last Split DateJun 1, 2020
    Split TypeForward split
    Split Ratio3:1

    Peer Position

    Against 11 similar companies, EW has the 2nd highest P/E.

    P/E Ratio35.8x vs 19.5x median
    P/S Ratio9.1x vs 3.5x median
    ROIC7.46% vs 8.43% median
    Revenue Growth (Trailing 4 Quarters, YoY)+13.44% vs +8.50% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 11.03% and EPS growth at 15.01% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+11.03%
    EPS Growth Forecast (2Y CAGR)+15.01%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EW

    What is EW's market cap?

    Edwards Lifesciences has a market cap of $61.59B. Its enterprise value, which adds debt and subtracts cash, is $59.16B.

    What is EW's P/E ratio?

    Edwards Lifesciences has a trailing P/E ratio of 35.8x and a forward P/E of 34.0x.

    How many shares of EW are outstanding?

    Edwards Lifesciences has 576.30M shares outstanding. The count is down 1.44% from a year earlier.

    Does EW pay a dividend?

    No. Edwards Lifesciences does not pay a dividend.

    How much debt does EW have?

    Edwards Lifesciences has $679.60M of total debt and $3.11B of cash and equivalents, a net cash position of $2.43B.